Clinical Trials Browser

Phase 2 × binimetinib × 90 days × Clear all

NCT03971409 2026-04-17

InCITe

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05026983 2026-04-16

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Phase 2 Recruiting

Melanoma

NCT05564377 2026-04-16

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04061980 2026-04-13

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Phase 2 Active not recruiting

Thyroid Neoplasms

NCT05554367 2026-04-13

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Phase 2 Active not recruiting

GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms

NCT05564403 2026-04-13

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Phase 2 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT05286788 2026-04-08

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Phase 2 Recruiting

Craniopharyngioma

NCT05170334 2026-04-06

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Phase 2 Active not recruiting

Uveal Melanoma, Eye Neoplasms

NCT04221438 2026-04-01

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Phase 2 Terminated

3 enrolled 11 charts

Lymphatic Metastasis, Melanoma

NCT04322383 2026-03-31

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT04324112 2026-03-31

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT04074096 2026-03-25

BEPCOME-MB

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

98 enrolled 18 charts 2 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

Melanoma, Skin Neoplasms

NCT05554354 2026-03-03

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Phase 2 Terminated

Anatomic Stage IV Breast Cancer AJCC v8